Nan Fung Group Holdings Ltd Acquires New Shares in Maplight Therapeutics, Inc. $MPLT

Nan Fung Group Holdings Ltd acquired a new position in Maplight Therapeutics, Inc. (NASDAQ:MPLT) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 971,253 shares of the company’s stock, valued at approximately $34,809,708,000. Maplight Therapeutics accounts for 26.5% of Nan Fung Group Holdings Ltd’s portfolio, making the stock its largest holding.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Fcpm Iii Services B.V. acquired a new position in shares of Maplight Therapeutics in the 4th quarter valued at $56,672,000. T. Rowe Price Investment Management Inc. purchased a new position in shares of Maplight Therapeutics during the 4th quarter worth $49,154,000. Goldman Sachs Group Inc. acquired a new stake in shares of Maplight Therapeutics during the 4th quarter worth about $34,026,000. BlackRock Inc. acquired a new stake in shares of Maplight Therapeutics during the 2nd quarter worth about $36,741,000. Finally, 5AM Venture Management LLC purchased a new stake in Maplight Therapeutics in the 4th quarter valued at about $16,687,000.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Jefferies Financial Group reaffirmed a “buy” rating on shares of Maplight Therapeutics in a research report on Monday, July 27th. Lifesci Capital upgraded shares of Maplight Therapeutics to a “strong-buy” rating in a research report on Thursday, May 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Maplight Therapeutics in a research note on Monday, July 13th. Raymond James Financial set a $31.00 price objective on shares of Maplight Therapeutics in a report on Friday, August 14th. Finally, BMO Capital Markets initiated coverage on shares of Maplight Therapeutics in a research report on Monday, July 20th. They set an “outperform” rating and a $46.00 price objective for the company. Four analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $29.67.

Insider Transactions at Maplight Therapeutics

In related news, insider James Woodruff Lillie sold 22,082 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $12.54, for a total transaction of $276,908.28. Following the completion of the transaction, the insider owned 202,380 shares in the company, valued at approximately $2,537,845.20. The trade was a 9.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Troy Cox bought 15,620 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The stock was acquired at an average cost of $9.52 per share, for a total transaction of $148,702.40. Following the acquisition, the director directly owned 15,620 shares of the company’s stock, valued at $148,702.40. The trade was a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 3.80% of the stock is owned by company insiders.

Maplight Therapeutics Trading Up 1.3%

MPLT stock opened at $11.36 on Tuesday. The company has a market capitalization of $526.88 million and a PE ratio of -0.27. Maplight Therapeutics, Inc. has a 12-month low of $9.10 and a 12-month high of $40.43. The business’s fifty day moving average price is $25.24 and its 200 day moving average price is $24.25.

Maplight Therapeutics (NASDAQ:MPLT) last announced its earnings results on Thursday, August 13th. The company reported ($1.32) EPS for the quarter, beating analysts’ consensus estimates of ($1.40) by $0.08. Research analysts predict that Maplight Therapeutics, Inc. will post -5.12 EPS for the current fiscal year.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.